Aliases & Classifications for Tooth Disease

MalaCards integrated aliases for Tooth Disease:

Name: Tooth Disease 12 15 17
Tooth Diseases 43 71
Tooth Disorders 42

Classifications:



External Ids:

Disease Ontology 12 DOID:1091
MeSH 43 D014076
SNOMED-CT 67 234947003
UMLS 71 C0040435

Summaries for Tooth Disease

MedlinePlus : 42 What are teeth? Your teeth are made of a hard, bonelike material. There are four parts: Enamel, your tooth's hard surface Dentin, the hard yellow part under the enamel Cementum, the hard tissue that covers the root and keeps your teeth in place Pulp, the soft connective tissue in the center of your tooth. It contains nerves and blood vessels. You need your teeth for many activities that you may take for granted. These include eating, speaking and even smiling. What are tooth disorders? There are many different problems that can affect your teeth, including Tooth decay - damage to a tooth's surface, which can lead to cavities Abscess - a pocket of pus, caused by a tooth infection Impacted tooth - a tooth did not erupt (break through the gum) when it should have. It is usually wisdom teeth that are impacted, but it can sometimes happen to other teeth. Misaligned teeth (malocclusion) Tooth injuries such as broken or chipped teeth What causes tooth disorders? The causes of tooth disorders varies, depending on the problem. Sometimes the cause is not taking good care of your teeth. In other cases, you may have been born with the problem or the cause is an accident. What are the symptoms of tooth disorders? The symptoms can vary, depending on the problem. Some of the more common symptoms include Abnormal color or shape of the tooth Tooth pain Worn-down teeth How are tooth disorders diagnosed? Your dentist will ask about your symptoms, look at your teeth, and probe them with dental instruments. In some cases, you may need dental x-rays. What are the treatments for tooth disorders? The treatment will depend on the problem. Some common treatments are Fillings for cavities Root canals for cavities or infections that affect the pulp (inside of the tooth) Extractions (pulling teeth) for teeth that are impacted and causing problems or are too damaged to be fixed. You may also have a tooth or teeth pulled because of overcrowding in your mouth. Can tooth disorders be prevented? The main thing that you can do to prevent tooth disorders is to take good care of your teeth: Brush your teeth twice a day with a fluoride toothpaste Clean between your teeth every day with floss or another type of between-the-teeth cleaner Limit sugary snacks and drinks Don't smoke or chew tobacco See your dentist or oral health professional regularly

MalaCards based summary : Tooth Disease, also known as tooth diseases, is related to charcot-marie-tooth disease, axonal, type 2b1 and charcot-marie-tooth disease, axonal, type 2p, and has symptoms including snoring, halitosis and toothache. An important gene associated with Tooth Disease is MFN2 (Mitofusin 2), and among its related pathways/superpathways is Neural Crest Differentiation. The drugs Ketamine and Folic acid have been mentioned in the context of this disorder. Affiliated tissues include bone, testes and brain, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Tooth Disease

Diseases related to Tooth Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 520)
# Related Disease Score Top Affiliating Genes
1 charcot-marie-tooth disease, axonal, type 2b1 35.1 MFN2 LRSAM1 LMNA GDAP1
2 charcot-marie-tooth disease, axonal, type 2p 35.0 LRSAM1 LITAF GDAP1
3 charcot-marie-tooth disease, dominant intermediate d 35.0 SH3TC2 MPZ KIF1B
4 charcot-marie-tooth disease, axonal, type 2t 35.0 SH3TC2 SBF2 LRSAM1 GDAP1
5 charcot-marie-tooth disease, dominant intermediate c 35.0 MPZ GJB1 GDAP1
6 charcot-marie-tooth disease, recessive intermediate a 34.9 MFN2 HSPB8 GDAP1
7 charcot-marie-tooth disease, dominant intermediate e 34.9 SH3TC2 SBF2 MTMR2 MPZ GDAP1
8 charcot-marie-tooth disease, type 4k 34.9 SH3TC2 LITAF
9 charcot-marie-tooth disease, axonal, type 2h 34.9 LRSAM1 GDAP1
10 charcot-marie-tooth disease, dominant intermediate a 34.9 MPZ GJB1 GDAP1
11 charcot-marie-tooth disease, axonal, type 2n 34.9 KIF1B GDAP1
12 charcot-marie-tooth disease, axonal, type 2r 34.9 LRSAM1 GDAP1
13 charcot-marie-tooth disease, dominant intermediate b 34.9 SH3TC2 SBF2 MTMR2 MPZ LITAF GJB1
14 charcot-marie-tooth disease, axonal, type 2a1 34.9 MPZ MFN2 LRSAM1 KIF1B HSPB8 GDAP1
15 charcot-marie-tooth disease, axonal, type 2w 34.8 MPZ MFN2 GJB1 GDAP1
16 charcot-marie-tooth disease, axonal, type 2d 34.8 SH3TC2 NEFL MPZ MFN2 KIF1B HSPB8
17 charcot-marie-tooth disease, type 4b3 34.8 SH3TC2 SBF2 PMP22 MTMR2 MPZ GDAP1
18 charcot-marie-tooth disease, axonal, type 2j 34.8 SH3TC2 SBF2 NEFL MTMR2 MPZ KIF1B
19 charcot-marie-tooth disease, type 4h 34.8 SH3TC2 SBF2 NDRG1 MTMR2 MPZ GDAP1
20 charcot-marie-tooth disease, type 4b1 34.8 SH3TC2 SBF2 MTMR2 MPZ LITAF GDAP1
21 charcot-marie-tooth disease, axonal, type 2b2 34.8 NEFL MPZ MFN2 MED25 LRSAM1 KIF1B
22 charcot-marie-tooth disease, type 4j 34.8 SH3TC2 SBF2 MTMR2 MPZ LITAF GDAP1
23 charcot-marie-tooth disease, demyelinating, type 1f 34.8 SBF2 NEFL MTMR2 MPZ LITAF KIF1B
24 charcot-marie-tooth disease, axonal, type 2k 34.7 HSPB8 GDAP1
25 charcot-marie-tooth disease, axonal, type 2l 34.7 NEFL MPZ MFN2 KIF1B HSPB8 HSPB1
26 charcot-marie-tooth disease type 2a2a 34.7 MFN2 LRSAM1
27 charcot-marie-tooth disease x-linked recessive 4 34.7 MPZ GJB1
28 charcot-marie-tooth disease, axonal, type 2i 34.7 SH3TC2 NEFL MPZ MED25 KIF1B HSPB8
29 charcot-marie-tooth disease, type 4b2 34.7 SH3TC2 SBF2 MTMR2 MPZ LITAF GJB1
30 charcot-marie-tooth disease, demyelinating, type 1d 34.7 PMP22 MTMR2 MPZ LITAF KIF1B GJB1
31 charcot-marie-tooth disease, axonal, type 2f 34.6 NEFL MPZ MFN2 LITAF KIF1B HSPB8
32 charcot-marie-tooth disease, type 4c 34.6 SH3TC2 SBF2 NDRG1 MTMR2 MPZ LITAF
33 charcot-marie-tooth disease, demyelinating, type 1b 34.6 SH3TC2 SBF2 PMP22 MTMR2 MPZ MFN2
34 charcot-marie-tooth disease, x-linked recessive, 2 34.6 MPZ MFN2 LITAF GJB1 EGR2
35 charcot-marie-tooth disease, axonal, type 2b 34.6 SH3TC2 SBF2 NEFL MTMR2 MPZ LITAF
36 charcot-marie-tooth disease type 2a 34.6 MFN2 KIF1B
37 charcot-marie-tooth disease, type 4d 34.6 SH3TC2 SBF2 NDRG1 MTMR2 MPZ LITAF
38 charcot-marie-tooth disease, demyelinating, type 4f 34.6 SH3TC2 SBF2 MTMR2 MPZ LITAF GJB1
39 charcot-marie-tooth disease, type 4a 34.5 SH3TC2 SBF2 MTMR2 MPZ MFN2 LITAF
40 charcot-marie-tooth disease, x-linked dominant, 1 34.5 SH3TC2 PMP22 NEFL MTMR2 MPZ MFN2
41 charcot-marie-tooth disease, demyelinating, type 1a 34.5 SH3TC2 SBF2 PMP22 NEFL MTMR2 MPZ
42 charcot-marie-tooth disease type x 34.3 SH3TC2 PMP22 MPZ MFN2 LITAF KIF1B
43 charcot-marie-tooth disease, demyelinating, type 1c 34.3 SH3TC2 SBF2 PMP22 NEFL MTMR2 MPZ
44 charcot-marie-tooth disease intermediate type 34.3 SH3TC2 SBF2 MTMR2 MPZ MFN2 LRSAM1
45 neuropathy, hereditary motor and sensory, russe type 34.3 SH3TC2 NDRG1 GDAP1 EGR2
46 hereditary motor and sensory neuropathy, type iic 34.2 SH3TC2 NEFL MPZ MFN2 KIF1B HSPB8
47 charcot-marie-tooth disease, axonal, type 2e 34.1 SH3TC2 SBF2 PMP22 NEFL NDRG1 MTMR2
48 charcot-marie-tooth disease and deafness 34.0 SH3TC2 SBF2 PMP22 NEFL NDRG1 MTMR2
49 charcot-marie-tooth disease 34.0 SH3TC2 SBF2 PMP22 NEFL NDRG1 MTMR2
50 roussy-levy hereditary areflexic dystasia 33.9 PMP22 MPZ

Graphical network of the top 20 diseases related to Tooth Disease:



Diseases related to Tooth Disease

Symptoms & Phenotypes for Tooth Disease

UMLS symptoms related to Tooth Disease:


snoring, halitosis, toothache, poor dentition

GenomeRNAi Phenotypes related to Tooth Disease according to GeneCards Suite gene sharing:

26 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.16 GJB1
2 Decreased viability GR00055-A-2 10.16 GJB1
3 Decreased viability GR00107-A-1 10.16 HSPB8
4 Decreased viability GR00221-A-1 10.16 HSPB8
5 Decreased viability GR00221-A-4 10.16 HSPB8
6 Decreased viability GR00240-S-1 10.16 LMNA
7 Decreased viability GR00249-S 10.16 GJB1 HSPB1 LMNA MPZ NDRG1 SH3TC2
8 Decreased viability GR00301-A 10.16 HSPB8
9 Decreased viability GR00381-A-1 10.16 FGD4 FIG4 HSPB1 LRSAM1 MPZ SH3TC2
10 Decreased viability GR00381-A-3 10.16 MPZ
11 Decreased viability GR00386-A-1 10.16 EGR2 LMNA LRSAM1 MED25 MPZ NEFL
12 Decreased viability GR00402-S-2 10.16 FGD4 GJB1 LRSAM1 MPZ MTMR2 NDRG1
13 Increased gamma-H2AX phosphorylation GR00053-A 9.23 EGR2 GJB1 HSPB1 LMNA MPZ NDRG1

MGI Mouse Phenotypes related to Tooth Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.39 EGR2 FGD4 FIG4 GDAP1 GJB1 HSPB8
2 growth/size/body region MP:0005378 10.18 EGR2 FGD4 FIG4 GJB1 HSPB1 KIF1B
3 homeostasis/metabolism MP:0005376 10.18 EGR2 GDAP1 GJB1 HSPB1 HSPB8 KIF1B
4 mortality/aging MP:0010768 10.07 EGR2 FIG4 GJB1 HSPB8 KIF1B LMNA
5 limbs/digits/tail MP:0005371 9.92 EGR2 FIG4 GDAP1 KIF1B LMNA MED25
6 nervous system MP:0003631 9.91 EGR2 FGD4 FIG4 GDAP1 GJB1 HSPB8
7 muscle MP:0005369 9.76 FIG4 HSPB8 KIF1B LMNA MFN2 NDRG1
8 skeleton MP:0005390 9.28 EGR2 FIG4 KIF1B LMNA MED25 MFN2

Drugs & Therapeutics for Tooth Disease

Drugs for Tooth Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 72)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
2
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
3 Trace Elements Phase 4
4 Vitamins Phase 4
5 Nutrients Phase 4
6 Micronutrients Phase 4
7 Antioxidants Phase 4
8 Protective Agents Phase 4
9 Analgesics Phase 4
10 Excitatory Amino Acid Antagonists Phase 4
11 Neurotransmitter Agents Phase 4
12 Anesthetics, General Phase 4
13 Anesthetics, Dissociative Phase 4
14 Anesthetics, Intravenous Phase 4
15 Alpha-lipoic Acid Phase 4
16 Vitamin B Complex Phase 4
17 Folate Phase 4
18 Thioctic Acid Phase 4
19 Vitamin B9 Phase 4
20
Ibuprofen Approved Phase 3 15687-27-1 3672
21
Caffeine Approved Phase 3 58-08-2 2519
22
Acetylcarnitine Approved, Investigational Phase 2, Phase 3 3040-38-8 7045767
23
Naltrexone Approved, Investigational, Vet_approved Phase 3 16590-41-3 5360515
24
Sorbitol Approved Phase 3 50-70-4 5780
25
Baclofen Approved Phase 3 1134-47-0 2284
26
Vitamin C Approved, Nutraceutical Phase 2, Phase 3 50-81-7 5785 54670067
27 Central Nervous System Stimulants Phase 3
28 Analgesics, Non-Narcotic Phase 3
29 Phosphodiesterase Inhibitors Phase 3
30 Cyclooxygenase Inhibitors Phase 3
31 Anti-Inflammatory Agents, Non-Steroidal Phase 3
32 Antirheumatic Agents Phase 3
33 carnitine Phase 2, Phase 3
34 Pharmaceutical Solutions Phase 3
35 Hematinics Phase 2, Phase 3
36 Neuroprotective Agents Phase 2, Phase 3
37 Epoetin alfa Phase 2, Phase 3 113427-24-0
38
Mexiletine Approved, Investigational Phase 2 31828-71-4 4178
39
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 1, Phase 2 303-98-0 5281915
40 Ubiquinone Phase 1, Phase 2
41 Ulipristal acetate Phase 2 126784-99-4
42
Methamphetamine Approved, Illicit 537-46-2 10836
43
Dopamine Approved 51-61-6, 62-31-7 681
44
Iodine Approved, Investigational 7553-56-2 807
45
Povidone-iodine Approved 25655-41-8
46
Povidone Approved 9003-39-8
47
Ethanol Approved 64-17-5 702
48
Chlorhexidine Approved, Vet_approved 55-56-1 9552079 2713
49
tannic acid Approved 1401-55-4
50
Benzocaine Approved, Investigational 94-09-7, 1994-09-7 2337

Interventional clinical trials:

(show top 50) (show all 110)
# Name Status NCT ID Phase Drugs
1 Success Rate Evaluation of Miniature Pulpotomy With MTA in Primary Molars Unknown status NCT02286648 Phase 4 Formocresol;Mineral Trioxide Aggregate
2 Effect of Racemic Ketamine on Pain in Females and Males After Surgical Removal of Third Molars Completed NCT00232492 Phase 4 Placebo males;Ketamine 0,1 mg/kg males;Ketamine 0,3 mg/kg males;Ketamine 0,5 mg/kg males;Placebo females;Ketamine 0,1 mg/kg females;Ketamine 0,3 mg/kg females;Ketamine 0,5 mg/kg females
3 The Association of Alpha Lipoic Acid to the Median Nerve Decompression in the Carpal Tunnel Syndrome: a Randomized Controlled Trial. Completed NCT01895621 Phase 4
4 Lidocaine and Triamcinolone vs Saline Trigger Point Injection for Treatment of Chronic Abdominal Wall Pain Withdrawn NCT02748395 Phase 4 Triamcinolone;Lidocaine
5 A Multicenter Study to Evaluate the Effects on Charcot−Marie−Tooth Neuropathy Type 1A of a Composite Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program. Unknown status NCT01289704 Phase 2, Phase 3
6 International, Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study Assessing in Parallel Groups the Efficacy and Safety of 2 Doses of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Treated 15 Months Completed NCT02579759 Phase 3 PXT3003 dose 1;PXT3003 dose 2;placebo
7 A Randomized, Placebo-controlled, Double Masked 120 Subject "Futility Design" Clinical Trial of Ascorbic Acid Treatment of Charcot Marie Tooth Disease Type 1A. Completed NCT00484510 Phase 2, Phase 3 Ascorbic acid (Vitamin C);placebo
8 A Single-centre, Double-blind, Randomised, Two-stage, Parallel-group Study to Assess the Efficacy and Safety of the Fixed Dose Combination of Ibuprofen 400 mg and Caffeine 100 mg Versus Ibuprofen 400 mg, Caffeine 100 mg and Placebo in Patients With Postoperative Dental Pain Completed NCT01929031 Phase 3 ibuprofen + caffeine;ibuprofen;ibuprofen;caffeine;ibuprofen + caffeine;placebo;placebo;caffeine;ibuprofen;ibuprofen + caffeine
9 Acetyl-l-carnitine to Enhance Nerve Regeneration in Carpal Tunnel Syndrome; a Randomized Control Trial. Completed NCT02141035 Phase 2, Phase 3 Acetyl-l-carnitine;placebo
10 Clinical Evaluation of Cemented and Angulated Screw-retained Crowns Following Immediate Implant Placement: a Randomized Controlled Clinical Trials Recruiting NCT04160247 Phase 3
11 International, Multi-center, Open Label, 9-month Follow-up Extension Study Assessing the Long-term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A Active, not recruiting NCT03023540 Phase 3 PXT3003
12 Recombinant Human Erythropoietin (r-HuEPO) in the Prevention of Neurologic Sequelae From Malignant Spinal Cord Compression: a Multi-Center, Placebo-Controlled, Phase 2 Randomized Study Terminated NCT00220675 Phase 2, Phase 3 Erythropoietin infusion
13 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Unknown status NCT02967679 Phase 1, Phase 2 MD1003
14 The Influence of Pronator Teres Release in the Treatment of Median Nerve Compression Neuropathy: A Randomized Prospective Study Unknown status NCT01562860 Phase 2
15 Mexiletine for Muscle Cramps in Charcot Marie Tooth Disease Completed NCT02561702 Phase 2 Mexiletine
16 A Phase II, Randomized, Placebo-controlled Trial of the Safety, Efficacy, Pharmacodynamics and Pharmacokinetics of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A. Completed NCT01401257 Phase 2 PXT3003 Low dose;PXT3003 Intermediate Dose;PXT3003 High Dose
17 Effects of Coenzyme Q10 (CoQ10) on Subjects With Charcot-Marie-Tooth Disease (CMT):A Double Blind, Randomized, Controlled Trial With an Open Label Follow-up Study Completed NCT00541164 Phase 1, Phase 2 Coenzyme Q10
18 Phase 2 Study of Ascorbic Acid Treatment in Charcot-Marie-Tooth Type 1A Completed NCT00271635 Phase 2 Placebo;ascorbic acid
19 Neuropathy Along the Median Nerve: Etiology of Symptoms Associated With the Carpal Tunnel Syndrome, a Preliminary Study Completed NCT00634738 Phase 1, Phase 2
20 A Randomized Controlled Clinical Trial of Regenerative Protocols to Treat Immature Necrotic Teeth Active, not recruiting NCT01827098 Phase 2
21 Phase I/IIa Trial Evaluating scAAV1.tMCK.NTF3 for Treatment of Charcot-Marie-Tooth Neuropathy Type 1A (CMT1A) Not yet recruiting NCT03520751 Phase 1, Phase 2 scAAV1.tMCK.NTF3
22 A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Charcot-Marie-Tooth Disease Terminated NCT03254199 Phase 2 FLX-787-ODT (orally disintegrating tablet);Placebo ODT
23 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X Terminated NCT03124459 Phase 2 ACE-083;Placebo
24 An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) Previously Enrolled in Study A083-02 and in Patients With Charcot-Marie Tooth (CMT) Disease Types 1 and X Previously Enrolled in Study A083-03 Terminated NCT03943290 Phase 2 ACE-083
25 LONG-TERM EFFECTS TOLERANCE AND THE Ulipristal Acetate IN DISEASE Charcot-MARIE-TOOTH TYPE OF 1A Terminated NCT02600286 Phase 2 EllaOne;EllaOne placebo
26 Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers Unknown status NCT02596191
27 Quantification of Nerve Stiffness in Patients With Peripheral Neuropathies Unknown status NCT03397303
28 Development of the Charcot-Marie-Tooth Disease Infant Scale (CMTInfS) for Infants With CMT Unknown status NCT02979145
29 Evaluation of the Analgesic Efficiency of the Transcutaneous Neurostimulation in the Charcot Syndrome Marie Tooth on the Pains of Lower Limbs Unknown status NCT01918826
30 Clinical Evaluation of Three Different Universal Adhesives and a Universal Flowable Composite for Restoration of Non-carious Cervical Lesions Unknown status NCT03415412
31 Clinical Performance of a Newly Developed Glass Ionomer Restorative Material for Posterior Restorations in an Adolescent Population Unknown status NCT02705729
32 Clinical Trial of Safety and Efficacy of the Medical Item Collagen Plates With Hydroxyapol Inducing Angiogenesis, "Nukleostim", for Bone Tissue Regeneration Unknown status NCT02293031
33 Regenerative Endodontic Procedure of Immature Permanent Teeth With Apical Periodontitis Using Platelet-rich Fibrin : A Pilot Randomized Controlled Trial Unknown status NCT02801552
34 Linkage and Identification of (a) Candidate Gene(s) for Tooth Disorders Unknown status NCT00026026
35 Muscle Oxygenation Modification During Effort in 4 Groups of Neuromuscular Diseases Compared to Healthy Controls, and Mitochondrial Function and Phenotype Assessment Unknown status NCT02789059
36 Clinical and Genetic Features of Familial Neuropathy Completed NCT00149045
37 Correlation Between Clinical and Electrophysiological Phenotypes in a Population of Patients With Neuropathy Charcot-Marie-Tooth Disease Type 1A Completed NCT01750710
38 Development and Validation of a Disability Severity Index for Charcot Marie Tooth Disease Completed NCT01455623
39 Survey of Current Management of Orthopaedic Complications in Charcot Marie Tooth Disease Patients Completed NCT02001038
40 Disability Severity Scale (DSI) and Hereditary Motor and Sensory Neuropathy Overall Disability Scale (HMSN-R-ODS) Completed NCT02194010
41 A Prospective Randomized-controlled Evaluation of Nanotite and Osseotite Surfaced Implant Performance in Graduate Student Programs Completed NCT00726063
42 A Prospective, Multicenter, Randomized Multicenter Study of Short Implants Used to Obviate the Need for Sinus Augmentation: an Assessment of Clinical Outcomes and Resource Allocation. Completed NCT00725049
43 An Analysis of the Symptomatic Domains Most Relevant to Charcot Marie Tooth Neuropathy (CMT) Patients Completed NCT02429947
44 MRI of the Brachial Plexus and Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Assessment of DTI-derived Measurements at 3.0-T Completed NCT03460951
45 Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Completed NCT02011204
46 Performance and Tolerability of a New Medical Device Coating Gel for the Temporary Relief of Teething Symptoms: a Randomized, Open Label, Parallel-group, Multicentre Study Completed NCT03423784
47 A Prospective, Randomized-Controlled, Multicenter Study of NanoTite Implants Placed Into Fresh Sinus Lift Augmentation Sites Completed NCT00713206
48 Patient Reported Outcomes Measures (PROM) in Carpal Tunnel Therapies in Patients With Inherited Neuropathies Completed NCT02788734
49 A Prospective, Observational Study of Immediate Loading Cases Using Osseotite Certain Tapered Implants Completed NCT01529762
50 A Randomized Double Blind Longitudinal Study to Determine Motor Unit Number Index Variability in CMT1A Patients Undergoing a Home Ankle Strengthening Program Versus Standard of Care Completed NCT03715283

Search NIH Clinical Center for Tooth Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Camphor
CAMPHOR CRYSTALS
CAMPHOR GUM
CAMPHOR,MONOBROMATED

Cochrane evidence based reviews: tooth diseases

Genetic Tests for Tooth Disease

Anatomical Context for Tooth Disease

MalaCards organs/tissues related to Tooth Disease:

40
Bone, Testes, Brain, Spinal Cord, Skin, Skeletal Muscle, Thyroid

Publications for Tooth Disease

Articles related to Tooth Disease:

(show top 50) (show all 3091)
# Title Authors PMID Year
1
Success and Behavior During Atraumatic Restorative Treatment, the Hall Technique, and the Stainless Steel Crown Technique for Primary Molar Teeth. 42
32522320 2020
2
Are Information Technologies Capable of Stimulating the Use of Dental Floss by Adolescents? A Cluster Randomised Clinical Trial. 42
32515412 2020
3
Preoperative Mouthwash in Subjects with Different Periodontal Status: A Randomised Controlled Clinical Trial. 42
32515413 2020
4
Bi-allelic mutations in HARS1 severely impair histidyl-tRNA synthetase expression and enzymatic activity causing a novel multisystem ataxic syndrome. 61
32333447 2020
5
Electrodiagnostic accuracy in polyneuropathies: supervised learning algorithms as a tool for practitioners. 61
32518996 2020
6
Mutations in heat shock protein beta-1 (HSPB1) are associated with a range of clinical phenotypes related to different patterns of motor neuron dysfunction: A case series. 61
32334137 2020
7
Diagnostic yield of targeted sequential and massive panel approaches for inherited neuropathies. 61
32506583 2020
8
High glucose level as a modifier factor in CMT1A patients. 61
32347995 2020
9
Psychoacoustics and neurophysiological auditory processing in patients with Charcot-Marie-Tooth disease types 1A and 2A. 61
32478888 2020
10
Pathological mutations in PNKP trigger defects in DNA single-strand break repair but not DNA double-strand break repair. 61
32504494 2020
11
Neuropathy-associated histidyl-tRNA synthetase variants attenuate protein synthesis in vitro and disrupt axon outgrowth in developing zebrafish. 61
32543048 2020
12
Telocytes in the Normal and Pathological Peripheral Nervous System. 61
32560571 2020
13
Neuron-specific knockdown of solute carrier protein SLC25A46a induces locomotive defects, an abnormal neuron terminal morphology, learning disability, and shortened lifespan. 61
32140609 2020
14
Genotype-phenotype correlation in a novel ABHD12 mutation underlying PHARC syndrome. 61
32077159 2020
15
A Deregulated Stress Response Underlies Distinct INF2-Associated Disease Profiles. 61
32444357 2020
16
Alanyl-tRNA synthetase 1 (AARS1) gene mutation in a family with intermediate Charcot-Marie-Tooth neuropathy. 61
32314272 2020
17
Genetic spectrum of MCM3AP and its relationship with phenotype of Charcot-Marie-Tooth disease. 61
32319184 2020
18
BAG3 Myopathy Presenting With Prominent Neuropathic Phenotype and No Cardiac or Respiratory Involvement: A Case Report and Literature Review. 61
32453099 2020
19
Validation of the Italian version of the Charcot-Marie-Tooth disease Pediatric Scale. 61
32394473 2020
20
A Consensus Statement on the Surgical Treatment of Charcot-Marie-Tooth Disease. 61
32478578 2020
21
Early onset demyelinating Charcot-Marie-Tooth disease caused by a novel in-frame isoleucine deletion in peripheral myelin protein 2. 61
32277537 2020
22
Discovery of 6-Phenylhexanamide Derivatives as Potent Stereoselective Mitofusin Activators for the Treatment of Mitochondrial Diseases. 61
32506913 2020
23
Peripheral myelin protein 22 preferentially partitions into ordered phase membrane domains. 61
32513719 2020
24
Structural and functional divergence of GDAP1 from the glutathione S-transferase superfamily. 61
32274853 2020
25
Charcot-Marie-Tooth disease: experience from a large Italian tertiary neuromuscular center. 61
31902012 2020
26
The MICOS complex, a structural element of mitochondria with versatile functions. 61
32229686 2020
27
The suspected SARS-Cov-2 infection in a Charcot-Marie-Tooth patient undergoing postsurgical rehabilitation: the value of telerehabilitation for evaluation and continuing treatment. 61
32317558 2020
28
Clinical and radiological characterization of novel FIG4-related combined system disease with neuropathy. 61
32385905 2020
29
The formin INF2 in disease: progress from 10 years of research. 61
32451589 2020
30
FIG4 mutations leading to parkinsonism and a phenotypical continuum between CMT4J and Yunis Varón syndrome. 61
32268254 2020
31
GARS-related disease in infantile spinal muscular atrophy: Implications for diagnosis and treatment. 61
32181591 2020
32
[Research advance of underlying pathogenesis and target therapies in Charcot-Marie-Tooth disease type 1A]. 61
32335891 2020
33
Pregnancy outcome in Charcot-Marie-Tooth disease: results of the CMT-NET cohort study in Germany. 61
32400062 2020
34
A novel homozygous variant extending the peripheral myelin protein 22 by 9 amino acids causes early-onset Charcot-Marie-Tooth disease with predominant severe sensory ataxia. 61
32412171 2020
35
Comprehensive genetic sequence and copy number analysis for Charcot-Marie-Tooth disease in a Canadian cohort of 2517 patients. 61
32376792 2020
36
HDAC6 inhibitors: Translating genetic and molecular insights into a therapy for axonal CMT. 61
32006555 2020
37
Gene therapies for axonal neuropathies: Available strategies, successes to date, and what to target next. 61
32001243 2020
38
De novo variants in SLC12A6 cause sporadic early-onset progressive sensorimotor neuropathy. 61
31439721 2020
39
Pes cavovarus in Charcot-Marie-Tooth compared to the idiopathic cavovarus foot: A preliminary weightbearing CT analysis. 61
32507338 2020
40
Closed arthrodesis in infected neuropathic ankles using Ilizarov ring fixation. 61
32228076 2020
41
Pmp22 Super-enhancer Deletion Causes Tomacula Formation and Conduction Block in Peripheral Nerves. 61
32356557 2020
42
7T MR neurography-ultrasound fusion for peripheral nerve imaging. 61
31899543 2020
43
Optic Neuropathy in Charcot-Marie-Tooth Disease. 61
32441898 2020
44
Quality of life in hereditary neuropathy with liability to pressure palsies is as impaired as in Charcot-Marie-Tooth disease type 1A. 61
32335868 2020
45
Peak Cough Flow in Children with Neuromuscular Disorders. 61
32095889 2020
46
Hereditary polyneuropathy with optic atrophy due to PDXK variant leading to impaired Vitamin B6 metabolism. 61
32522499 2020
47
Unfolded protein response in myelin disorders. 61
31638085 2020
48
BAG3 p.Pro209Ser mutation identified in a Chinese family with Charcot-Marie-Tooth disease. 61
31853710 2020
49
Cochlear implantation in patient with Charcot-Marie-Tooth disease. 61
32265048 2020
50
Novel EGR2 variant that associates with Charcot-Marie-Tooth disease when combined with lipopolysaccharide-induced TNF-α factor T49M polymorphism. 61
32337334 2020

Variations for Tooth Disease

Expression for Tooth Disease

Search GEO for disease gene expression data for Tooth Disease.

Pathways for Tooth Disease

Pathways related to Tooth Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.81 PMP22 MPZ GJB1

GO Terms for Tooth Disease

Cellular components related to Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.93 SBF2 NEFL NDRG1 MTMR2 MFN2 LRSAM1
2 endosome membrane GO:0010008 9.26 SBF2 MTMR2 LITAF FIG4
3 axon cytoplasm GO:1904115 8.8 NEFL KIF1B HSPB1

Biological processes related to Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol metabolic process GO:0046488 9.4 MTMR2 FIG4
2 mitochondrial fusion GO:0008053 9.37 MFN2 GDAP1
3 negative regulation of endocytosis GO:0045806 9.32 MTMR2 LRSAM1
4 negative regulation of myelination GO:0031642 9.26 MTMR2 FIG4
5 myelination GO:0042552 9.26 SBF2 PMP22 MPZ EGR2
6 peripheral nervous system myelin maintenance GO:0032287 9.16 SH3TC2 NDRG1
7 myelin assembly GO:0032288 8.8 PMP22 MTMR2 FIG4

Molecular functions related to Tooth Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 SH3TC2 SBF2 PMP22 NEFL NDRG1 MTMR2
2 phosphatidylinositol-3-phosphatase activity GO:0004438 8.62 MTMR2 FIG4

Sources for Tooth Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....